Table 2 Clinical and immunological characteristics of study participants: Bahir Dar Felege Hiwot Referral Hospital, Northwest Ethiopia April, 2018 (n = 539)
Variables | Frequency | Percentage |
|---|---|---|
Presence of eating problem | ||
Yes | 106 | 19.7 |
No | 433 | 80.3 |
Type of eating problem (n = 106) | ||
Loss of appetite | 17 | 16.1 |
Vomiting | 54 | 50.9 |
Loss of appetite plus vomiting | 31 | 29.2 |
Othersa | 4 | 3.8 |
Presence of GI symptoms | ||
Yes | 137 | 25.4 |
No | 402 | 74.6 |
Type of GI symptoms (n = 137) | ||
Diarrhea | 51 | 37.2 |
Indigestion | 48 | 35.0 |
Constipation | 31 | 22.7 |
Othersb | 7 | 5.1 |
Presence of opportunistic infection | ||
Yes | 258 | 47.9 |
No | 281 | 52.1 |
Type of opportunistic infection (n = 258) | ||
TB | 164 | 63.6 |
Oral lesion | 40 | 15.5 |
Chronic diarrhea | 31 | 12.0 |
Othersc | 23 | 8.9 |
WHO stage of HIV | ||
Stage I | 207 | 38.4 |
Stage II | 84 | 15.6 |
Stage III | 214 | 39.7 |
Stage IV | 34 | 6.3 |
CD4 count | ||
< 200 cells | 44 | 8.2 |
200–350 cells | 164 | 30.4 |
> 350 cells | 331 | 61.4 |
Patients current treatment regimen | ||
1c (AZT + 3TC + NVP) | 145 | 26.9 |
1d (AZT + 3TC + EFV) | 65 | 12.1 |
1e (TDF + 3TC + EFV) | 191 | 35.4 |
1f (TDF + 3TC + NVP) | 43 | 8.0 |
2 h (TDF + 3TC + Atazanavir) | 55 | 10.2 |
2f (AZT + 3TC + Atazanavir) | 22 | 4.1 |
Others d | 18 | 3.3 |